Mirai's machine intelligence-based, open platform unlocks delivery to any tissue and cell type through rapid, iterative learning of in vivo tested chemistries Co-optimization of cargo design and manufacturing ensure the best possible medicine and manufacturing strategy for each new program Company emerges with an initial commitment of $50 million from Flagship Pioneering CAMBRIDGE, Mass. , Sept. 26, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Mirai Bio , a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines.
Mirai's machine intelligence-based, open platform uses proprietary data algorithms and machine intelligence to unlock delivery to any tissue and cell type, optimize cargo design, and facilitate manufacturing, accelerating genetic medicines toward successful clinical translation for the company's partners. Mirai plans to further advance its platform with Flagship's initial commitment of $50 million , aiming to enhance and accelerate genetic medicine development across a wide range of therapeutic areas and modalities. "We are in the age of information molecules, yet enormous technological challenges in the delivery, cargo design, and manufacturing of these molecules have hindered the speedy and full realization of their potential," said Hari Pujar , Ph.
D., Founding President of Mirai and Operating Partner at Flagship Pioneering. "We crea.
